This article is more than 5 years old. Information may no longer be current.
FDA clears IND application for Oyster Point's dry eye treatment
Click Here to Manage Email Alerts
The FDA has cleared an investigational new drug application for Oyster Point Pharma’s dry eye disease treatment OC-01, the company announced in a press release.
OC-01, a nicotine acetylcholine receptor agonist, is an investigational compound that stimulates natural tear film production via a nasal spray. This clearance will support ongoing phase 2 clinical trials of OC-01 and OC-02, a similar compound, for the treatment of signs and symptoms of dry eye disease, the release said. OC-02 received IND clearance in October 2017.
“Our innovative pharmaceutical approach leverages the parasympathetic nervous system by stimulating the glands responsible for producing natural tear film. Delivered through a nasal spray, as opposed to traditional eye drops, this therapy has the potential to immediately reduce the symptoms of dry eye,” Oyster Point CEO Jeffrey Nau, PhD, said in the release. “Clearance of our IND application for OC-01 allows us to quickly advance this therapy into phase 2 clinical trials.”